A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. N Engl J Med 2015
Times Cited: 4461




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
3


Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, Maria I Markou, Erifili E Hatziagelaki, Charalampos A Grassos, Maria L Velliou, John D Barbetseas. Am J Cardiovasc Drugs 2021
0

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021
0

Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2.
Maximilian Hopf, Christof Kloos, Gunter Wolf, Ulrich Alfons Müller, Nicolle Müller. J Clin Med 2021
0

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Nan Ye, Meg J Jardine, Megumi Oshima, Carinna Hockham, Hiddo J L Heerspink, Rajiv Agarwal, George Bakris, Aletta E Schutte, Clare Arnott, Tara I Chang,[...]. Circulation 2021
2

Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Muhammad Imtiaz Ahmad, Michael D Shapiro. Curr Atheroscler Rep 2021
0

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
0


Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
Gian Pio Sorice, Francesca Cinti, Lucia Leccisotti, Domenico D'Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Camilla Cocchi, Umberto Capece, Pietro Manuel Ferraro,[...]. Diabetes Ther 2021
0

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Elias A Sanidas, Dimitrios P Papadopoulos, Erifili Hatziagelaki, Charalampos Grassos, Maria Velliou, John Barbetseas. Am J Hypertens 2020
5



Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
2


The Evolving Understanding and Approach to Residual Cardiovascular Risk Management.
Devinder S Dhindsa, Pratik B Sandesara, Michael D Shapiro, Nathan D Wong. Front Cardiovasc Med 2020
7


Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3


Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels.
Mi Seon Seo, Hee Seok Jung, Jin Ryeol An, Minji Kang, Ryeon Heo, Hongliang Li, Eun-Taek Han, Se-Ran Yang, Eun-Hee Cho, Young Min Bae,[...]. Toxicol Appl Pharmacol 2020
0

Consensus paper on the evaluation and treatment of resistant hypertension by the Turkish Society of Cardiology.
Asife Sahinarslan, Emine Gazi, Meryem Aktoz, Cigdem Ozkan, Gülay Ulusal Okyay, Ozgul Ucar Elalmis, Erdal Belen, Reviewers Atila Bitigen, Ulver Derici, Neslihan Bascil Tutuncu,[...]. Anatol J Cardiol 2020
1

SGLT2 Inhibitors in Resistant Hypertension: A Sweet Solution.
Karen C Tran, Swapnil Hiremath. Am J Hypertens 2020
0

The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
Ian J Neeland, Bjorn Eliasson, Takatoshi Kasai, Nikolaus Marx, Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, Isabella Zwiener, Brian S Wojeck, Henry K Yaggi,[...]. Diabetes Care 2020
1

Sodium-Glucose Cotransporter-2 Inhibitor Immediately Decreases Serum Uric Acid Levels in Type 2 Diabetic Patients.
Naro Ohashi, Taro Aoki, Takashi Matsuyama, Sayaka Ishigaki, Shinsuke Isobe, Tomoyuki Fujikura, Takuya Hashimoto, Daisuke Tsuriya, Hiroshi Morita, Akihiko Kato,[...]. Med Sci Monit 2020
1